A Study of Modified Stem Cells in Traumatic Brain Injury (TBI)



Status:Active, not recruiting
Conditions:Hospital, Neurology
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:18 - 75
Updated:5/5/2018
Start Date:January 2016
End Date:April 2019

Use our guide to learn which trials are right for you!

A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)

The primary purpose of the clinical study is to evaluate the clinical efficacy of
intracranial administration of SB623 cells on patients with chronic motor deficit from
Traumatic Brain Injury. A secondary purpose of the study is 1) to evaluate the effect of
intracranial administration of SB623 cells on disability parameters and 2) to evaluate the
safety and tolerability of intracranial administration of SB623 cells. Patients with stable,
chronic motor deficits secondary to focal traumatic brain injury must be 12 months post TBI.

SB623 cells are adult bone-marrow-derived cells that are transiently transfected with a
plasmid construct encoding the intracellular domain of human Notch-1. These cells produce
trophic factors that protect neurons in models of ischemic insult. In a rat contusion model
of TBI, implantation of SB623 around the area of the injury resulted in significant
improvement of motor function. Further, safety evaluation of animal models implanted with
SB623 cells have shown no adverse effects and no SB623-related clinical, laboratory, or
histological abnormalities were found. A 2-year Phase 1/2A dose escalation study
(NCT01287936) of SB623 stereotactically implanted into the brains of patients with chronic
motor deficits due to ischemic stroke has completed.The study has shown
statistically-significant improvements in motor function in each of three scales: the
European Stroke Scale (ESS), the National Institute of Health Stroke Scale (NIHSS) and the
Fugl-Meyer scale. The study showed no serious adverse events likely attributed to SB623, and
only minor adverse events mostly grade 1 or 2 (with one grade 3) that were unrelated,
unlikely related, or possibly related to SB623. No dose-limiting toxicities were observed.

Inclusion Criteria:

- Documented history of TBI, with correlated MRI or CT

- At least 12 months post-TBI

- Focal cerebral injury able to be identified on MRI (+/- concomitant diffuse axonal
injury)

- Neurological motor deficit substantially due to focal cerebral injury observed on MRI

- GOS-E score of 3-6 (i.e. moderate or severe disability)

- Require Motricity Index 10-81 (UE Scale) and/or 10-78 (LE Scale)

- Able and willing to undergo computed tomography (CT) and magnetic resonance imaging
(MRI)

- Subjects must be willing to participate in study related exercises to the extent
possible

- Able to undergo all planned neurological assessments

Exclusion Criteria:

- History or presence of any other major neurological disease

- Any seizures in the prior 3 months

- The presence of contracture at any joints that would interfere with interpretation of
any of the neurological assessments (e.g. contracture preventing the detection of any
increase in the range of motion or ability to perform a task)

- Other neurologic, neuromuscular or orthopedic disease that limits motor function

- Clincially significant finding on MRI of brain not related to TBI

- Known presence of any malignancy except squamous or basal cell carcinoma of the skin

- History of CNS malignancy

- Positive findings on tests for occult malignancy, unless a non-malignant etiology is
confirmed

- Uncontrolled systemic illness, including, but not limited to: hypertension (systolic
>150 mm Hg or diastolic >95 mm Hg); diabetes; renal, hepatic, or cardiac failure

- Uncontrolled major psychiatric illness, including depression symptoms (CESD-R Scale of
≥16)

- Unexplained abnormal preoperative test values (blood tests, electrocardiogram [ECG],
chest X-ray); x-ray evidence of infection; uncontrolled atrial fibrillation or
uncontrolled congestive heart failure

- Presence of craniectomy (without bone flap replacement) or other contraindication to
stereotactic surgery

- Participation in any other investigational trial within 4 weeks of initial screening
or within 7 weeks of study entry

- Botulinum toxin injection, phenol injection, intrathecal baclofen, or any other
interventional treatments for spasticity (except bracing and splinting) 16 weeks priot
to the Baseline visit.

- Ongoing use of other non-traditional drugs

- Substance use disorder (per DSM-V criteria, including drug or alcohol)

- Contraindications to head CT or MRI

- Pregnant or lactating

- Female patients of childbearing potential unwilling to use an adequate birth control
method during the 12 months of the study
We found this trial at
21
sites
Atlanta, Georgia 30312
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30322
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
96 Jonathan Lucas Street
Charleston, South Carolina 29425
?
mi
from
Charleston, SC
Click here to add this to my saved trials
345 E Superior St
Chicago, Illinois 60611
(312) 238-1000
Rehabilitation Institute of Chicago The Rehabilitation Institute of Chicago (RIC) is an independent, 501(c)3, non-profit...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Columbus, Ohio
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Elkins Park, Pennsylvania 19027
?
mi
from
Elkins Park, PA
Click here to add this to my saved trials
Englewood, Colorado 80113
?
mi
from
Englewood, CO
Click here to add this to my saved trials
Los Angeles, California 90095
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Miami, Florida 33144
?
mi
from
Miami, FL
Click here to add this to my saved trials
339 East 38th Street
New York, New York 10016
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Oceanside, CA
Click here to add this to my saved trials
101 The City Drive South
Orange, California 92868
?
mi
from
Orange, CA
Click here to add this to my saved trials
200 Lothrop Street
Pittsburgh, Pennsylvania 15213
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Placentia, California 92870
?
mi
from
Placentia, CA
Click here to add this to my saved trials
Richland, Washington 99352
?
mi
from
Richland, WA
Click here to add this to my saved trials
Richmond, Virginia 23298
(804) 828-0100
Virginia Commonwealth University Since our founding as a medical school in 1838, Virginia Commonwealth University...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Santa Monica, California 90404
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
?
mi
from
Sapporo,
Click here to add this to my saved trials
?
mi
from
Stamford, CT
Click here to add this to my saved trials
300 Pasteur Drive
Stanford, California 94305
?
mi
from
Stanford, CA
Click here to add this to my saved trials
White Plains, New York 10605
?
mi
from
White Plains, NY
Click here to add this to my saved trials